The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
Open accessAbstract
A within-group risk factor analysis was conducted to predict angiographic change in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of colestipol plus niacin therapy in men with previous coronary bypass surgery. Global angiographic change, including both native coronary arteries and bypass grafts after 2 treatment years, was the end point. Risk factors included on-trial clinical measures, plasma lipids, lipoproteins, and apolipoproteins. Univariate analysis indicated that risk factors previously observed by others in epidemiologic investigation of ischemic heart disease--total cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein B, and diastolic blood pressure--had significant effects in the placebo-treated group. Univariate analysis indicated significant effects of apolipoprotein C-III in drug- and placebo-treated groups. Multivariate analysis indicated the predominant risk factor predicting the probability of global coronary progression was non-HDL cholesterol in placebo-treated subjects and the content of apolipoprotein C-III in high density lipoproteins of drug-treated subjects. Both drug- and placebo-treated group findings point to an important role for triglyceride-rich lipoproteins in progression and regression of human atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The value of non-HDL-C in CVD risk assessment was first proposed by Frost and Havel in 1998, 61 and this relationship has now been confirmed in many studies. [203]3][204][205][206][207][208][209][210][211][212][213][214][215][216]”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [207]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
Burstein, M., Scholnick, H. R., & Morfin, R. F. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42943-8 · Cited by 2,500
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Self-citationSur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérum
Burstein, M., & Samaille, J. (1960) · Clinica Chimica Acta · doi:10.1016/0009-8981(60)90075-9 · Cited by 620
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 498
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493
Levy, R. I., Brensike, J. F., Epstein, S. E., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., & Battaglini, J. W. (1984) · Circulation · doi:10.1161/01.cir.69.2.325 · Cited by 437
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Self-citationSoutar, A. K., Garner, C. W., Baker, H. N., Sparrow, J. T., Jackson, R. L., Gotto, A. M., & Smith, L. C. (1975) · Biochemistry · doi:10.1021/bi00685a003 · Cited by 392
Windler, E., Chao, Y., & Havel, R. J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70647-4 · Cited by 365
Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.
Shelburne, F. A., Hanks, J., Meyers, W., & Quarfordt, S. H. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109710 · Cited by 358
Kuusi, T., Saarinen, P., & Nikkilä, E. A. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90251-8 · Cited by 336
Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314
Role of Specific Glycopeptides of Human Serum Lipoproteins in the Activation of Lipoprotein Lipase
Havel, R. J., Shore, V. G., SHORE, B., & Bier, D. M. (1970) · Circulation Research · doi:10.1161/01.res.27.4.595 · Cited by 310
Curry, M. D., Alaupovic, P., & Suenram, C. A. (1976) · Clinical Chemistry · doi:10.1093/clinchem/22.3.315 · Cited by 286
Self-citationCurry, M. D., Gustafson, A., Alaupovic, P., & McConathy, W. J. (1978) · Clinical Chemistry · doi:10.1093/clinchem/24.2.280 · Cited by 172
Self-citationQuantitative determination of human apolipoprotein Cc-III by electroimmunoassay
Curry, M. D., McConathy, W. J., Fesmire, J. D., & Alaupovic, P. (1980) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(80)90016-8 · Cited by 140
Self-citationCarlson, L. A., & Ballantyne, D. (1976) · Atherosclerosis · doi:10.1016/0021-9150(76)90016-2 · Cited by 139
Dynamics of apolipoprotein E metabolism in humans
Blum, C. B. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38036-6 · Cited by 136
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, methods, and baseline results
Blankenhorn, D. H., Johnson, R. L., Nessim, S., Azen, S. P., Sanmarco, M. E., & Selzer, R. H. (1987) · Controlled Clinical Trials · doi:10.1016/0197-2456(87)90156-5 · Cited by 118
Self-citationLe, N. A., Gibson, J. C., & Ginsberg, H. N. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38512-6 · Cited by 103
Alaupovic, P. (1981) · Canadian Journal of Biochemistry · doi:10.1139/o81-079 · Cited by 69
Self-citationAlaupovic, P., Wj, M., Fesmire, J. D., Tavella, M. J., & Bard, J. (1988) · PubMed · Cited by 66
Self-citationLipoproteins and lipoprotein metabolism
Eisenberg, S. (1983) · Journal of Molecular Medicine · doi:10.1007/bf01486366 · Cited by 54
Postprandial exchange of apolipoprotein C-III between plasma lipoproteins
Barr, S. I., Kottke, B. A., & Mao, S. J. (1981) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/34.2.191 · Cited by 30
Isolation of apolipoprotein-free lipoprotein lipase from human post-heparin plasma
Ganesan, D., & Bradford, R. H. (1971) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(71)90648-6 · Cited by 24
Flagged first, then by citations
Cited by
Sorted by citations
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
Self-citationRelation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Metadata
- Authors
- Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P.
- Affiliations
- University of Southern California (US)
- ORCID
- Alaupovic, P
- Venue
- Circulation
- Published
- 1990-02
- Volume
- 81
- Issue
- 2
- Pages
- 470-476
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2092138949
- Cited by
- 278
- References
- 32
- Citations by year
- 2026: 1 · 2025: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 6
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oklahoma Medical Research Foundation
- National Institutes of Health (5p01hl023619-10)
- National Heart, Lung, and Blood Institute (HL 23619)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- coronary artery disease progression, aortocoronary bypass graft, native coronary arteries, colestipol, nicotinic acid, cholesterol-lowering therapy, risk factors, non-HDL cholesterol, apolipoprotein C-III, HDL cholesterol, triglyceride-rich lipoproteins, apolipoprotein B, LDL cholesterol, triglycerides, diastolic blood pressure, atherosclerosis regression
- MeSH terms
- Coronary Artery Bypass, Apolipoproteins, Apolipoproteins C, Colestipol, Coronary Artery Disease, Humans, Lipids, Male, Middle Aged, Niacin, Recurrence, Multivariate Analysis, Randomized Controlled Trials as Topic, Coronary Angiography, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
